环孢素眼液能明显改善干燥综合症眼干
发表者：收集
日期：2015-03-10
浏览次数：1075
评论次数：0
摘要 目的：评价局部用0.05%环孢素眼液治疗对人工泪液无效的轻、中和重度干眼病的疗效。
方法：该研究为一项前瞻性临床研究，共有158例对人工泪液无效的干眼病患者（如干燥综合症眼干），根据疾病严重性分为3组：轻度、中度和重度组。采用眼表面疾病症状改善指数、泪膜破裂时间、荧光染色、丽丝胺绿（lissamine green）染色和滤纸试验来评价患者，观察3-16个月，主要观测疾病改善情况。
结果：轻度、中度和重度干眼病患者的改善率分别为74.1%（46/62）、72.4% (50/69) 和66.7% (18/27)，总体改善率为72.1%。
结论：局部用环孢素A滴眼对轻中重干眼病均有效，其中，轻度干眼病组的症状改善最大，严重干眼病组的体征改善最好。
附原文：OBJECTIVE: To evaluate the use of topical cyclosporine, 0.05% (Restasis; Allergan Inc, Irvine, California), for the treatment of mild, moderate, and severe dry eye disease unresponsive to artificial tears therapy. METHODS: This was a prospective clinical study. One hundred fifty-eight consecutive patients with dry eye disease unresponsive to artificial tears therapy were divided into 3 groups of disease severity: mild, moderate, and severe. Patients were evaluated using the Ocular Surface Disease Index for symptomatic improvement, tear breakup time, fluorescein staining, lissamine green staining, and Schirmer testing. Patients were observed for 3 to 16 months. The main outcome measure was improvement in disease. RESULTS: Forty-six of 62 patients with mild dry eye disease (74.1%), 50 of 69 with moderate disease (72.4%), and 18 of 27 with severe disease (66.7%) showed improvement, with 72.1% improving overall. CONCLUSIONS: Topical cyclosporine shows beneficial effects in all categories of dry eye disease. Symptomatic improvement was greatest in the mild group and the best results in improvement of disease signs were in patients with severe dry eye disease.
引自：Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol, 2008，126(8):1046-50 （注：干燥综合症病人或亲属可加QQ群交流，群号： 118194945 ，本网站站长私人微信号： ssgzz88 ）
方法：该研究为一项前瞻性临床研究，共有158例对人工泪液无效的干眼病患者（如干燥综合症眼干），根据疾病严重性分为3组：轻度、中度和重度组。采用眼表面疾病症状改善指数、泪膜破裂时间、荧光染色、丽丝胺绿（lissamine green）染色和滤纸试验来评价患者，观察3-16个月，主要观测疾病改善情况。
结果：轻度、中度和重度干眼病患者的改善率分别为74.1%（46/62）、72.4% (50/69) 和66.7% (18/27)，总体改善率为72.1%。
结论：局部用环孢素A滴眼对轻中重干眼病均有效，其中，轻度干眼病组的症状改善最大，严重干眼病组的体征改善最好。
附原文：OBJECTIVE: To evaluate the use of topical cyclosporine, 0.05% (Restasis; Allergan Inc, Irvine, California), for the treatment of mild, moderate, and severe dry eye disease unresponsive to artificial tears therapy. METHODS: This was a prospective clinical study. One hundred fifty-eight consecutive patients with dry eye disease unresponsive to artificial tears therapy were divided into 3 groups of disease severity: mild, moderate, and severe. Patients were evaluated using the Ocular Surface Disease Index for symptomatic improvement, tear breakup time, fluorescein staining, lissamine green staining, and Schirmer testing. Patients were observed for 3 to 16 months. The main outcome measure was improvement in disease. RESULTS: Forty-six of 62 patients with mild dry eye disease (74.1%), 50 of 69 with moderate disease (72.4%), and 18 of 27 with severe disease (66.7%) showed improvement, with 72.1% improving overall. CONCLUSIONS: Topical cyclosporine shows beneficial effects in all categories of dry eye disease. Symptomatic improvement was greatest in the mild group and the best results in improvement of disease signs were in patients with severe dry eye disease.
引自：Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol, 2008，126(8):1046-50 （注：干燥综合症病人或亲属可加QQ群交流，群号： 118194945 ，本网站站长私人微信号： ssgzz88 ）